30 results about "Dominant-Negative Mutant" patented technology

The present invention provides a method of improving the efficiency of establishment of induced pluripotent stem (iPS) cells, comprising inhibiting the p53 function in the step of somatic cell nuclear reprogramming. The inhibition of p53 function is achieved by bringing a substance selected from the group consisting of (1) chemical inhibitors of p53, (2) dominant negative mutants of p53 and nucleic acids that encode the same, (3) siRNAs and shRNAs against p53 and DNAs that encode the same, and (4) p53 pathway inhibitors, into contact with a somatic cell, and the like. The present invention also provides an agent for improving the efficiency of establishment of iPS cells, the agent comprising an inhibitor of p53 function, particularly (1) chemical inhibitors of p53, (2) dominant negative mutants of p53 and nucleic acids that encode the same, (3) siRNAs and shRNAs against p53 and DNAs that encode the same, and (4) p53 pathway inhibitors. The present invention further provides a method of producing an iPS cell, comprising bringing a nuclear reprogramming substance and an inhibitor of p53 function into contact with a somatic cell.

An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells.A CAR expression vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding a T cell immune function-enhancing factor, wherein the nucleic acid encoding an immune function-enhancing factor is a nucleic acid encoding interleukin-7 and a nucleic acid encoding CCL19, a nucleic acid encoding a dominant negative mutant of SHP-1, or a nucleic acid encoding a dominant negative mutant of SHP-2, or a CAR-expressing T cell introduced with the CAR expression vector are prepared.

Disclosed are mutant CDK inhibitor (CKI) polypeptides having dominant negative antagonist activity against wild-type CKI proteins, as well as related compositions, including nucleic acids and vectors encoding the mutant CKI polypeptides and transformed host cells and transgenic plants comprising such nucleic acids and vectors. Also disclosed are related methods for using the mutant proteins to modulate cell division in cells, particularly plant cells.

The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and / or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.

Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.

The invention discloses a heat shock transcription factor 1 dominant negative effect mutant dn-Hsf1 and its application, belonging to the field of biotechnology. Human and A. flavus ( Aspergillus flavus ) in the heat shock transcription factor 1 HSF1 protein, and a total of 213 amino acid residues from the 576th to the 788th position of the C-terminal of the Aspergillus flavus Hsf1 protein were deleted to obtain the heat shock transcription factor 1 dominant negative mutant dn in Aspergillus flavus The amino acid sequence of the -Hsf1 protein is shown in SEQ ID NO.1, and the coding nucleotide sequence is shown in SEQ ID NO.2. The dominant-negative mutant dn-Hsf1 can inhibit the function of normal Hsf1 in fungi, thereby inhibiting the growth of fungi, and is used in the prevention and control of fungal pollution.

The present invention provides a genetically modified plant that biosynthesizes an increased amount of capsinoids, a method of producing the genetically modified plant, and a production method of capsinoids from the genetically modified plant. More particularly, the present invention provides a genetically modified plant capable of producing capsinoids, which shows a decreased expression or activity of an enzyme that catalyzes an amino group conversion reaction from vanillin to vanillylamine as compared to wild strains, and the like. As a method of suppressing expression or activity of an enzyme, an introduction of DNA encoding an antisense RNA, iRNA, ribozyme or dominant-negative mutant for the target gene, a destruction of the gene by a knockout method, mutagen treatment or transposon insertion, an introduction of a gene encoding an antibody against the enzyme and the like can be mentioned.

The present invention provides dominant negative mutants of FGF2 for suppressing FGF-mediated cellular signaling. Related compositions, methods, and kits are disclosed.

The invention provides a nontoxic anthrax live vaccine.The active ingredient of the nontoxic anthrax live vaccine includes a nontoxic anthrax strain for expressing anthrax protective antigen mutant protein (rPA).The nontoxic anthrax strain is obtained by performing locus mutation on pXO1 plasmid of an original Sterne vaccine strain, and locus mutation covers R178A and K197A double-locus mutants of a protective antigen.The live vaccine is prepared from the strain including the PA dominant negative mutants of the protective antigen, and has the advantages that the live vaccine loses the capability of being combined with lethal factors and edema factors, toxins cannot be generated, and it is proved that the immunogen of the live vaccine is not changed at all; meanwhile, biologically-inactivated rPA can be in competitive combination with cell receptors, and the purpose of neutralizing anthrax toxins can be achieved.The mutant strain completely loses the sporeforming function, the vaccine standard requirements for not harming operators and not causing environment pollution are met, subcutaneous injection and oral administration can be selected as administration routes, and the defect that a Sterne vaccine strain is not suitable for certain livestock due to large residual toxicity is overcome.

The invention provides a reporter gene carrier which comprises an AP2alpha specific cis acting element. The carrier is characterized in that the AP2alpha specific cis acting element consists of four GCCCGCGG nucleotide sequences connected in series, wherein the four GCCCGCGG nucleotide sequences are connected in series through a nucleotide sequence TT. The reporter gene carrier designed by the invention is easy to prepare, simple to operate and good in repeatability, and can effective transfect different mammalian cells. The carrier is more accurate and reliable than EMSA (Electrophoretic Mobility Shift Assay) when is used to detect activity change of a dominant negative mutant-mediated transcription factor. The carrier is suitable for in vitro study of biological activity of the AP2alpha transcription factor in various mammalian cells.